Six Rapport insiders buy the fade. The one who knew first was selling.Rapport Therapeutics · NASDAQ: RAPP
- What they did
- Six insiders bought roughly $1.57M of RAPP on the open market across 21–23 October, at $26.87–$27.84. None under a trading plan.
| Insider | Role | Date | Shares | Value | Account |
|---|---|---|---|---|---|
| Steven M. Paul | Director | 22 Oct | 35,714 | $974,277 | Fund LLC |
| John Maraganore | Director | 21–22 Oct | — | $249,000 | Personal |
| Troy Ignelzi | CFO | 21 Oct | 5,500 | $144,000 | Personal |
| Wendy Young | Director | 22 Oct | 3,789 | ~$100,000 | Personal |
| Paul M. Silva | Director | 22 Oct | — | $99,636 | Personal |
| Ramiro Sanchez | Director | 23 Oct | 3,600 | $98,460 | Personal · first ever |
| Abraham Ceesay | CEO | 6–7 Oct | −4,522 | −$143,000 | 10b5-1, adopted 27 Mar |
- The setting
- On 20 October Rapport reported positive Phase 2 topline for RAP-219 in acute bipolar mania: placebo-adjusted 3.1-point improvement on the Young Mania Rating Scale at week 3, p=0.045; CGI-BP-S mania p=0.024; no severe or serious treatment-emergent adverse events. The stock opened +36% premarket at $38.90 and closed the day at $28.60, up 3.74%. It fell a further 7.4% on 21 October. The insiders bought into that.
Consensus read
About as clean a conviction signal as the tape offers. Six people — four non-executive directors, the CFO, and a scientific heavyweight — put their own money in, discretionarily, with no plan to hide behind, in an open window immediately after a successful readout and a violent intraday fade.
Steelmanned: these are the people best placed to judge whether a 3.1-point delta is a real drug, they chose to act in the window where they have the most information and the least excuse, and they did it together.
Contrarian read
The cluster is a response to the fade, and the fade was informed. The market did not misread the win; it priced the magnitude. A 3.1-point placebo-adjusted YMRS delta at p=0.045 is roughly half the effect of the drugs already approved for this indication.
And the buying is smaller than it looks. Strip out the one purchase made from a fund rather than a pocket and five people put about $590K between them into a company holding $436M of cash. That is a governance gesture priced near the $100K round number, not five independent valuation judgements.
Evidence that discriminates
- The effect size against approved comparators in the same indication. RAP-219: 3.1 points placebo-adjusted on YMRS at week 3, p=0.045. Cariprazine’s registrational trial: LSMD −6.1 (3–6 mg) and −5.9 (6–12 mg), both p<.001. Olanzapine’s: 6.65 points, p<.001. RAP-219 delivers about half the benchmark on a p-value that would not survive a single pre-specified multiplicity correction. A cluster buy is consistent with both readings; the effect-size comparison is only consistent with the fade being informed. That is what makes it the crux rather than colour.
- The CEO is absent from the bid. Abraham Ceesay, who had the earliest sight of the readout timeline, sold 4,522 shares on 6–7 October at $30.66–$32.03 under a plan adopted 27 March. He retains 452,245 shares directly, so he is not exiting — but he is not buying either, and his own CFO, who signed that Form 4 as attorney-in-fact on 8 October, bought two weeks later. The six buyers are four outside directors, a finance chief and a fund. The scientific principal is not among them.
- 62% of the headline figure is not personal money. Steven M. Paul’s $974,277 was bought through Paul Capital Strategy III Fund LLC, reported as indirect ownership with a disclaimer of beneficial ownership beyond his pecuniary interest. The Form 4 ownership field says so; the headline “six insiders, $1.6M” does not.
- The sizes cluster, the convictions do not. $98,460 / $99,636 / ~$100,000 / $144,000. Four of the six land within 2% of $100K. Independent valuation judgements do not converge on a round number. (Inference. The amounts are from the filings; the reading is mine.)
Also inference: the cross-trial effect-size comparison is not a head-to-head. Placebo response in mania trials has risen over the decades, which compresses modern deltas for design reasons rather than drug reasons — RAP-219’s 15.4-point absolute reduction implies a placebo arm near 12.3 points, which is high. That is the strongest counter to my read and it is a real one.
What would falsify me
A Form 4 showing Ceesay making a discretionary open-market purchase, or terminating his 10b5-1 plan. The “principal absent from the bid” observation collapses and the cluster becomes a far stronger signal than I have allowed.
The Q1 2027 end-of-Phase-2 FDA meeting producing agreement on a registrational path at 0.75 mg without a demand for a larger effect. Then the effect-size objection loses most of its force, because the regulator will have priced the number and not blinked.
The same directors adding materially more at materially higher prices. A token gesture is not repeated into strength.
PatternSanchez: 0 → 3,600, a first purchase. The only other named-individual RAPP transaction reported in the first three weeks of October was the CEO’s sale. I did not verify the full prior-year insider history, so treat the “no comparable prior cluster” claim as reported rather than exhaustively checked.